Advances in immunosuppression for pancreas transplantation

Current Opinion in Organ Transplantation

Volumn 13, Issue 1, 2008, Pages 79-84

  Singh, Rajinder P ^a   Stratta, Robert J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody induction; Calcineurin inhibitors; Mycophenolate; Sirolimus; Steroid withdrawal; Tacrolimus

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

CLINICAL TRIAL; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY; MAINTENANCE THERAPY; MEDICAL LITERATURE; MONOTHERAPY; OUTCOME ASSESSMENT; PANCREAS; PANCREAS TRANSPLANTATION; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; UNITED STATES;

CALCINEURIN; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; PANCREAS TRANSPLANTATION; SIROLIMUS; STEROIDS;

EID: 38149024998     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282f2fd91     Document Type: Review

References (27)

1. Gruessner AC, Sutherland DER. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005; 19:433-455.
2. Andreoni KA, Brayman KL, Guidinger MK, et al. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007; 7:1359-1375. The 2006 Scientific Registry of Transplant Recipients comprehensive report of the status of kidney and pancreas transplantation in the US.
3. Farney A, Sundberg A, Moore P, et al. A randomized trial of alemtuzumab vs. antithymocyte globulin induction in renal and pancreas transplantation. Clin Transplant (in press).
4. Farney A, Rogers J, Ashcraft E, et al. Alemtuzumab versus rabbit antithymocyte globulin induction in kidney and pancreas transplantation: a prospective, randomized study [abstract]. Am J Transplant 2007; 7 (Suppl 2):233.
5. Kaufman DK, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction: long-term results. Am J Transplant 2006; 6:331-339. One of the first comparative studies of alemtuzumab versus rATG induction in an early steroid elimination protocol in SPK transplantation.
6. Stratta RJ, Alloway RR, Lo A, Hodge EE. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidneypancreas transplantation: results at 3 years. Transplant Proc 2005; 37:3531-3534.
7. Stratta RJ, Alloway RR, Lo A, et al. A prospective, randomized, multicenter trial of daclizumab induction in simultaneous kidney-pancreas transplantation: risk factors for rejection and adverse long-term outcomes at 3 years [abstract]. Am J Transplant 2006; 6 (WTC Suppl):105.
8. Zhang R, Florman S, Devidoss S, et al. The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy. Clin Transplant 2007; 21:583-589. A single center study of 5-year outcomes in a relatively large cohort of Caucasian and African-American SPK transplant recipients receiving basiliximab induction.
9. Zhang R, Florman S, Devidoss S, et al. A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy. Am J Transplant 2007; 7:1815-1821.
10. Becker LE, Nogueira VA, Abensur MP, et al. No induction versus anti-IL2R induction therapy in simultaneous kidney pancreas transplantation: A comparative analysis. Transplant Proc 2006; 38:1933-1936.
11. Sollinger HW, Odorico JS, Becker YT, et al. Campath vs. basiliximab after simultaneous pancreas-kidney transplantation. Am J Transplant (in press).
12. Schmied BM, Muller SA, Mehrabi A, et al. Immunosuppressive standards in simultaneous kidney-pancreas transplantation. Clin Transplant 2006; 20 (Suppl 17):44-50. An excellent recent overview of immunosuppressive strategies in pancreas transplantation.
13. Muthusamy ASR, Roy D, Elker DE, et al. Alemtuzumab induction and steroid free immunosuppression in pancreas transplantation [abstract]. Am J Transplant 2007; 7 (Suppl 2):251.
14. Aoun M, Eschewege P, Hamoudi Y, et al. Very early steroid withdrawal in simultaneous pancreas-kidney transplants. Nephrol Dial Transplant 2007; 22:899-905.
15. Fridell JA, Agarwal A, Powelson JA, et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. Transplantation 2006; 82:389-392. Successful steroid withdrawal in PAK transplant recipients.
16. Vessal G, Wiland AM, Philosophe B, et al. Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. Clin Transplant 2007; 21:491-497. Successful steroid withdrawal in all categories of solitary PTX recipients.
17. Saudek F, Malaise J, Boucek P, et al. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant 2005; 20 (Suppl 2):3-11.
18. Margreiter R, Malaise J, Pratschke J, et al. Sirolimus versus mycophenolate mofetil in tacrolimus-based primary simultaneous pancreas-kidney (SPK) transplantation: 6-month results of a multicenter trial [abstract]. Am J Transplant 2006; 6 (WTC Suppl):105.
19. Gruessner RWG, Sutherland D, Kandaswamy R, et al. Lessons learned from >500 pancreas (PA) transplants alone at a single institution [abstract]. Am J Transplant 2007; 7 (Suppl 2):249. A landmark experience with over 500 solitary pancreas transplants at a single center.
20. Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: one- and two-year outcomes. Transplantation 2006; 82:1621-1624. A unique experience with tacrolimus monotherapy in PTX.
21. Starzl TE, Murase N, Abu-Almagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361:1502.
22. Thai N, Khan A, Basu A, et al. Campath-1H induction in pancreas transplantation: FK monotherapy and FK/MMF [abstract]. Am J Transplant 2006; 6 (WTC Suppl):103-104.
23. Thai NL, Blisard D, Tom K, et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: correlation between low T-cell responses and infection. Transplantation 2006; 82:1649-1652. One of the first reports attempting to define targets for immune monitoring in PTX.
24. Knight RJ, Kerman RH, Zela S, et al. Pancreas transplantation utilizing Thymoglobulin, sirolimus, and cyclosporine. Transplantation 2006; 81: 1101-1105. Report describing a novel protocol in PTX with immune monitoring to guide immunosuppressant conversion.
25. Kaufman DB, Leventhal JR, Parker MA, Gallon LG. Calcineurin inhibitor-free/rapid steroid elimination immunosuppression in simultaneous pancreas-kidney transplantation [abstract]. Am J Transplant 2006; 6 (WTC Suppl):104.
26. Gallon LG, Winoto J, Chhabra D, et al. Long-term renal transplant function in recipients of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2007; 83:1324-1329. Long-term study of renal function in SPK transplant recipients receiving either tacrolimus/MMF or tacrolimus/sirolimus maintenance therapy.
27. Ming CS, Chen ZH. Progress in pancreas transplantation and combined pancreas-kidney transplantation. Hepatobiliary Pancreat Dis Int 2007; 6:17-23.